West Pharmaceutical Services (NYSE:WST) Announces Quarterly Earnings Results, Beats Estimates By $0.07 EPS

West Pharmaceutical Services (NYSE:WST) issued its earnings results on Thursday. The medical instruments supplier reported $1.82 earnings per share for the quarter, topping the consensus estimate of $1.75 by $0.07, Zacks reports. West Pharmaceutical Services had a net margin of 17.37% and a return on equity of 18.41%. West Pharmaceutical Services updated its FY 2025 guidance to 6.000-6.200 EPS.

West Pharmaceutical Services Trading Down 36.5 %

Shares of NYSE:WST traded down $117.56 during trading on Thursday, reaching $204.72. The company’s stock had a trading volume of 3,220,334 shares, compared to its average volume of 544,948. The company has a current ratio of 3.00, a quick ratio of 2.23 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services has a 12 month low of $201.82 and a 12 month high of $408.88. The firm’s 50 day simple moving average is $332.39 and its two-hundred day simple moving average is $315.13. The stock has a market capitalization of $14.83 billion, a PE ratio of 30.39, a price-to-earnings-growth ratio of 19.31 and a beta of 1.01.

West Pharmaceutical Services Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, February 11th. Investors of record on Friday, February 7th were issued a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.41%. The ex-dividend date of this dividend was Friday, February 7th. West Pharmaceutical Services’s payout ratio is 12.46%.

Analyst Ratings Changes

Several research analysts have commented on WST shares. StockNews.com raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating in a report on Tuesday. UBS Group raised shares of West Pharmaceutical Services from a “neutral” rating to a “buy” rating and increased their price objective for the company from $350.00 to $390.00 in a report on Thursday, December 12th. Citigroup started coverage on shares of West Pharmaceutical Services in a report on Wednesday, January 8th. They set a “buy” rating and a $400.00 price objective for the company. Wolfe Research started coverage on shares of West Pharmaceutical Services in a report on Friday, December 13th. They set a “peer perform” rating for the company. Finally, Bank of America increased their price objective on shares of West Pharmaceutical Services from $350.00 to $355.00 and gave the company a “buy” rating in a report on Friday, December 13th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $403.75.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.